Michael Rosenblatt
School of Medicine

Dr. Rosenblatt serves as Dean of Tufts University School of Medicine. He previously held the appointment of George R. Minot Professor of Medicine at Harvard Medical School and Chief of the Division of Bone and Mineral Metabolism Research at Beth Israel Deaconess Medical Center. He served as the President of Beth Israel Deaconess Medical Center from 1999-2001 and was previously the Harvard Faculty Dean and Senior Vice President for Academic Programs at CareGroup and Beth Israel Deaconess Medical Center. He was also a founder of the Carl J. Shapiro Institute for Education and Research at Harvard Medical School and Beth Israel Deaconess Medical Center, a joint venture whose mission is to manage the academic enterprise and promote academic innovation.

Dean Rosenblatt has served as Director of the Harvard-MIT Division of Health Sciences and Technology, during which time he led a medical education organization for M.D., Ph.D., and M.D.-Ph.D. training jointly sponsored by Harvard and MIT. He was Senior Vice President for Research at Merck Sharp & Dohme Research Laboratories where he headed the worldwide development team for alendronate (FOSAMAX), Merck's bisphosphonate for osteoporosis and bone disorders. In addition, he directed drug discovery efforts in molecular biology, bone biology and calcium metabolism, virology, cancer research, lipid metabolism, and cardiovascular research in the United States, Japan, and Italy. In Japan, he had responsibility for clinical research and development. In leading most of Merck's international research efforts, he established two major basic research institutes, one in Tsukuba, Japan, and one near Rome, Italy. He also headed Merck Research's worldwide University and Industry Relations Department.

He is the recipient of the Fuller Albright Award for his work on parathyroid hormone and the Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman's Award from Merck. His research is in the field of hormonal regulation of calcium metabolism, osteoporosis, and cancer metastasis to bone. His major research projects are in the design of peptide hormone antagonists (especially parathyroid hormone), isolation/characterization of receptors and mapping hormone--receptor interactions, elucidating the mechanisms by which breast and prostate cancer "home" to bone, study of the tumor-secreted parathyroid hormone-like protein, and osteoporosis and bone biology.

Dean Rosenblatt has chaired the Gordon Conference on Chemistry and Biology of Peptides, and served on the NIH Physiological Chemistry Study Section and the Board of Scientific Counselors of the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH. He has been elected to the American Society of Clinical Investigation, the Association of American Physicians, to Fellowship in the American Association for the Advancement of Science, and the presidency of the American Society of Bone and Mineral Research. He has testified before a Senate Hearing on U.S. biomedical research priorities in 1997.

From 1981 to 1984, Dean Rosenblatt served as Chief of the Endocrine Unit, Massachusetts General Hospital. He received his undergraduate degree summa cum laude from Columbia and his M.D. magna cum laude from Harvard. His internship, residency, and endocrinology training were all at the Massachusetts General Hospital.

Dean-at-a-Glance

Michael Rosenblatt

Title:

Dean of the School of Medicine

Academic Credentials:

B.A., Summa cum laude, Columbia University (1969); M.D., Magna cum laude, Harvard Medical School (1973)

Tufts Affiliations

Dean, Tufts University School of Medicine; Professor of Physiology and Medicine, School of Medicine; Member, Cellular and Molecular Physiology program, Sackler School of Graduate Biomedical Sciences

Former Positions & Professorships

Chief, Division of Bone and Mineral Metabolism Research, Beth Israel Deaconess Medical Center (2002-2003); Visiting Scientist, Children's Hospital (2002); Visiting Scientist, The Whitehead Institute, Massachusetts Institute of Technology (2001-2002); George R. Minot Professor of Medicine, Harvard Medical School (1998-2003); Harvard Faculty Dean for Academic Programs, Beth Israel Deaconess Medical Center and CareGroup (1996-2000); Executive Director, Carl J. Shapiro Institute for Education and Research (1996-2000)

Research Interests

Dean Rosenblatt's research is in the field of hormonal regulation of calcium metabolism, osteoporosis and cancer metastasis to bone.

Notable Honors

Election to the Association of Osteobiology (1994); Fellow, American Association for the Advancement of Science (1993); Who's Who in the World (1993); Invited to submit nomination for the Nobel Prize in Medicine or Physiology (1992, 1994, 1996, 2002); Chairman's Award, Merck & Company (1989); Citation of Appreciation, Japan Endocrine Society (1988), Fuller Albright Young Investigator Award, American Society for Bone and Mineral Research, for "outstanding scientific achievement in the field of bone and mineral metabolism" (1986); Soma Weiss Award of the Harvard Medical Society for the best research paper presented to the Undergraduate Assembly (1973)

Related Web Sites

Tufts University School of Medicine

E-Mail

Michael.Rosenblatt@tufts.edu